iPSC-Derived Cardiomyocyte Therapy for Heart Failure from Japan
iPSC-derived cardiomyocyte therapy involves induced pluripotent stem cells differentiated into cardiomyocytes for injection to repair heart tissue after myocardial infarction. These engineered cell cultures are classified as cell therapy products under tariff item 3002.51.00.
Duty Rate — Japan → Canada
0%
Import Tips
• Confirm that the product meets Health Canada's requirements for cell therapy, including evidence of differentiation and purity
• Provide a certificate of analysis and details on the cell culture process to the CBSA
• Arrange for customs clearance with a licensed broker familiar with biological products